Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855131 | 0.91 | CYP2D6 (0.46) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL23699729 | 0.82 | CYP2D6 (0.40) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL23699755 | 0.81 | CYP2D6 (0.68) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL21855130 | 0.73 | CYP2D6 (0.62) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL7781184 | 0.72 | CYP2D6 (0.66) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL28096156 | 0.72 | HPGD (0.43) | CYP2D6TSHRCA9CA12CA2 | |
| SCHEMBL357546 | 0.70 | CYP2D6 (0.64) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL11287638 | 0.70 | CYP2D6 (0.64) | CYP2D6TSHRFBP1CA9CA12 | |
| SCHEMBL3941394 | 0.70 | HDAC1 (0.57) | CA9CA12CA2NPC1RAB9A | |
| SCHEMBL3945926 | 0.70 | HDAC1 (0.57) | CA9CA12CA2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-3866773-B1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV GEORGIA STATE RES FOUND (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885FBP1 2413/4885 |
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885FBP1 2413/4885 |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885FBP1 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.